Senesco Technologies, Inc. FD Bruce Galton Brian Ritchie Chief Executive Officer (brian.ritchie@fd.com) (bgalton@senesco.com) (212) 850-5683 (732) 296-8400 SENESCO TECHNOLOGIE

TECHNOLOGIES RECEIVES NOTICE OF NON COMPLIANCE FROM AMEX

NEW BRUNSWICK, N.J. (November 4, 2009) - Senesco

Technologies, Inc. (the "Company") (NYSE Amex: SNT) has received a notice

from the NYSE Amex LLC ("NYSE") providing notification that, the Company does

not meet one of the NYSE's continued listing standards as set forth in Part 10

of the NYSE company guide and the Company has therefore become subject to the

procedures and requirements of Section 1009 of the NYSE company

guide. Specifically, the Company is not in compliance with Section

1003(a)(iii) of the NYSE company guide with stockholder's equity of less than

$6,000,000 and losses from continuing operations and/or net losses in its five

most recent fiscal years. The Company reported stockholder's equity

of $5,667,834 at June 30, 2009.

notice is based on a review by the NYSE of information which the Company has

publicly disclosed, including information contained in the Company's. Form 10-K

for the period ended June 30, 2009, which disclosed the financial status of the

Company at that time.

maintain an NYSE listing, Senesco must submit a plan by November 30, 2009

advising the NYSE of action it has taken, or will take that would bring Senesco

into compliance with the continued listing standards within a maximum of 18

months from the date of notification by the NYSE. The Company is taking steps to

prepare and submit such a plan to the NYSE on or before November 30,

Listings Qualifications Department of the NYSE will evaluate Senesco's plan and

determine whether it reasonably demonstrates the Company's ability to regain

compliance with the continued listing standards within 18 months. If the NYSE

accepts Senesco's plan, the Company may be able to continue its listing during

the plan period, provided that Senesco demonstrates progress consistent with its

plan and complies with other applicable NYSE listing qualifications. If the

Company fails to submit a satisfactory plan or fails to demonstrate progress

consistent with the plan accepted by the NYSE, the NYSE may initiate delisting

procedures. During the plan period Senesco will be subject to periodic review to

determine whether it is acheiving progress consistent with the

Senesco Technologies, Inc.

Technologies, Inc. is a U.S. biotechnology company, headquartered in New

Brunswick, NJ. Senesco has initiated preclinical research to trigger or

delay cell death in mammals (apoptosis) to determine if the technology is

applicable in human medicine. Accelerating apoptosis may have applications

to development of cancer treatments. Delaying apoptosis may have

applications to certain inflammatory and ischemic diseases. Senesco takes

its name from the scientific term for the aging of plant cells:

senescence. Delaying cell breakdown in plants extends freshness after

harvesting, while increasing crop yields, plant size and resistance to

environmental stress. The Company believes that its technology can be used

to develop superior strains of crops without any modification other than

delaying natural plant senescence. Senesco has partnered with leading-edge

companies engaged in agricultural biotechnology and earns research and

development fees for applying its gene-regulating platform technology to enhance

its partners' products.

Certain statements included in this

press release are forward-looking statements within the meaning of the Private

Securities Litigation Reform Act of 1995. Actual results could differ

materially from such statements expressed or implied herein as a result of a

variety of factors, including, but not limited to: the ability of the Company to

consummate additional financings; the development of the Company's gene

technology; the approval of the Company's patent applications; the successful

implementation of the Company's research and development programs and joint

ventures; the success of

the Company's license agreements; the acceptance by the market of the

Company's products; success of the Company's preliminary studies and preclinical

research; competition and the timing of projects and trends in future operating

performance, the Company's ability to comply with the continued listing

standards of the AMEX, as well as other factors expressed from time to time in

the Company's periodic filings with the Securities and Exchange Commission (the

"SEC"). As a result, this press

release should be read in conjunction with the Company's periodic filings with

the SEC. The forward-looking statements contained herein are made

only as of the date of this press release, and the Company undertakes no

obligation to publicly update such forward-looking statements to reflect

subsequent events or circumstances.